291 related articles for article (PubMed ID: 17873310)
1. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.
Kindmark H; Sundin A; Granberg D; Dunder K; Skogseid B; Janson ET; Welin S; Oberg K; Eriksson B
Med Oncol; 2007; 24(3):330-7. PubMed ID: 17873310
[TBL] [Abstract][Full Text] [Related]
2. Metastatic glucagonoma: treatment with liver transplantation.
Radny P; Eigentler TK; Soennichsen K; Overkamp D; Raab HR; Viebahn R; Mueller-Horvart C; Sotlar K; Rassner G
J Am Acad Dermatol; 2006 Feb; 54(2):344-7. PubMed ID: 16443073
[TBL] [Abstract][Full Text] [Related]
3. The glucagonoma syndrome. Clinical and pathologic features in 21 patients.
Wermers RA; Fatourechi V; Wynne AG; Kvols LK; Lloyd RV
Medicine (Baltimore); 1996 Mar; 75(2):53-63. PubMed ID: 8606627
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
[TBL] [Abstract][Full Text] [Related]
5. Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases.
El Rassi Z; Partensky C; Valette PJ; Berger F; Chayvialle JA
Eur J Surg Oncol; 1998 Dec; 24(6):562-7. PubMed ID: 9870735
[TBL] [Abstract][Full Text] [Related]
6. Glucagonoma syndrome.
Bloom SR; Polak JM
Am J Med; 1987 May; 82(5B):25-36. PubMed ID: 2884877
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration.
Santangelo WC; Unger RH; Orci L; Dueno MI; Popma JJ; Krejs GJ
Pancreas; 1986; 1(5):464-9. PubMed ID: 2882503
[TBL] [Abstract][Full Text] [Related]
8. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma.
Li W; Yang X; Deng Y; Jiang Y; Xu G; Li E; Wu Y; Ren J; Ma Z; Dong S; Han L; Ma Q; Wu Z; Wang Z
Sci Rep; 2022 May; 12(1):9053. PubMed ID: 35641533
[TBL] [Abstract][Full Text] [Related]
9. Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma.
Technau K; Renkl A; Norgauer J; Ziemer M
Eur J Dermatol; 2005; 15(2):110-2. PubMed ID: 15757825
[TBL] [Abstract][Full Text] [Related]
10. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour.
Eldor R; Glaser B; Fraenkel M; Doviner V; Salmon A; Gross DJ
Clin Endocrinol (Oxf); 2011 May; 74(5):593-8. PubMed ID: 21470282
[TBL] [Abstract][Full Text] [Related]
11. Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update.
Fenkci SM; Fidan Yaylali G; Sermez Y; Akdam H; Sabir N; Kiraç S
Endocr Relat Cancer; 2005 Jun; 12(2):449-54. PubMed ID: 15947115
[TBL] [Abstract][Full Text] [Related]
12. [Glucagonoma: a recent series of 7 cases].
Vauleon E; Egreteau J; Boucher E; Desfourneaux V; Bretagne JF; Raoul JL
Bull Cancer; 2004; 91(7-8):637-40. PubMed ID: 15381454
[TBL] [Abstract][Full Text] [Related]
13. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema.
Mullans EA; Cohen PR
J Am Acad Dermatol; 1998 May; 38(5 Pt 2):866-73. PubMed ID: 9591806
[TBL] [Abstract][Full Text] [Related]
14. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.
Tolliver S; Graham J; Kaffenberger BH
Int J Dermatol; 2018 Jun; 57(6):642-645. PubMed ID: 29450880
[TBL] [Abstract][Full Text] [Related]
15. [Glucagonoma revealed by necrolytic migratory erythema].
Bonaventure C; Merle P; Grezard P; Ruiz JM; Chevallier M; Scoazec JY; Trepo C
Gastroenterol Clin Biol; 2003 Feb; 27(2):230-2. PubMed ID: 12658134
[TBL] [Abstract][Full Text] [Related]
16. Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema?
Manes G; Pellegrini A; Riccardi F; Uomo G
Ital J Gastroenterol; 1995 Jun; 27(5):248-9. PubMed ID: 8541575
[TBL] [Abstract][Full Text] [Related]
17. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
Strosberg JR; Choi J; Cantor AB; Kvols LK
Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
[TBL] [Abstract][Full Text] [Related]
18. Necrolytic migratory erythema associated with glucagonoma syndrome: a case report.
Dal Coleto CC; de Mello AP; Piquero-Casals J; Lima FR; Vilela MA; Festa-Neto C; Sanches JA
Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(6):183-8. PubMed ID: 11836542
[TBL] [Abstract][Full Text] [Related]
19. Glucagonoma syndrome and necrolytic migratory erythema.
Lobo I; Carvalho A; Amaral C; Machado S; Carvalho R
Int J Dermatol; 2010 Jan; 49(1):24-9. PubMed ID: 20465606
[TBL] [Abstract][Full Text] [Related]
20. Effect of somatostatin in necrolytic migratory erythema of glucagonoma.
Elsborg L; Glenthøj A
Acta Med Scand; 1985; 218(2):245-9. PubMed ID: 2865872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
